SlideShare a Scribd company logo
2017 Version of LI-RADS for CT
and MR Imaging: An Update
DR.M.VINOTHKUMAR
Apollo speciality hospital
Introduction
 The Liver Imaging Reporting and Data System (LI-
RADS) is a reporting system created for the
standardized interpretation of liver imaging findings in
patients who are at risk for hepatocellular carcinoma
(HCC).
Overview of LI-RADS v2017
 In version 2017, new LI-RADS categories have
been introduced to better characterize
observations for both diagnosis and treatment
response assessment.
 New content is aimed primarily at addressing gaps
in prior versions, such as the lack of treatment
response criteria and specific criteria for inclusion
in the LR-M category (malignancy that may not be
HCC).
LI-RADS v2017 Diagnostic
Population
Inclusion criteria
 Adult (older than 18 years) patients with
cirrhosis,
 patients with chronic hepatitis B,
 patients with current or prior HCC with or
without cirrhosis, including adult liver
transplantation candidates and liver
transplant recipients.
Exclusion criteria
 Cirrhosis due to a vascular disorder (eg, hereditary
hemorrhagic telangiectasia, Budd-Chiari syndrome,
nodular regenerative hyperplasia, or cardiac
cirrhosis),
 cirrhosis due to congenital hepatic fibrosis,
 pediatric patients.
Cirrhosis caused by vascular disorders are excluded from the
LI-RADS diagnostic population because of the large number
of arterialized nonmalignant hepatocellular nodules that may
resemble HCC at imaging, which lowers diagnostic specificity
.
LR-NC (Not Categorizable)
 The newly added LR-NC category is intended to allow the
radiologist to defer designating a final LI-RADS category
when technical limitations (ie, image degradation or omission)
prevent the differential diagnosis from being meaningfully
narrowed.
 An observation ranged from probably benign to potentially
malignant because dynamic phase imaging had not been
performed, LR-NC would be an appropriate category.
 For LR-NC observations, repeat imaging performed with all
sequences at 3 months or sooner is usually appropriate or
depending on the cause of image degradation, imaging with
an alternative modality may be preferable.
LR-TIV (Definitely Malignant with TIV)
 An unequivocal TIV was previously categorized as
an LR-5V lesion, although other malignancies such
as cholangiocarcinoma and combination tumors
also can invade veins.
 Because TIVs can occur in non-HCC malignancies,
in LI-RADS v2017 the category LR-5 is replaced
with LRTIV, which can apply to HCC or other
malignancies
LR-M (probable or definite malignancy, not
specific for HCC)
 Prior versions include a list of ancillary
features that are suggestive of other
malignancies, but they do not provide
specific guidelines for application of the
features.
These features are most closely associated with
intrahepatic cholangiocarcinomas but may also be
present in combination tumors (eg,
hepatocholangiocarcinomas) and metastases.
LR-M (probable or definite malignancy, not specific for
HCC)
 The updated, more explicit criteria for inclusion in
the LR-M category are intended to preserve the
specificity of the LR-5 category for HCC without
loss of sensitivity for the detection of malignancy
and to improve inter-reader agreement.
 Many LR-M lesions represent HCC but do not meet
the imaging criteria for this diagnosis.
 Multidisciplinary discussion is usually required for
the appropriate management of LR-M lesions.
Changes to Major Feature Definitions
Threshold growth
 Minimal 5-mm increase in lesion size and either a 50% or
greater increase in size before or at 6 months or a 100% or
greater increase in size after 6 months.
 A lesion that was previously unseen for up to 24 months but is
now 10 mm in diameter or larger also is considered to have
threshold growth.
 It is imperative to perform comparative measurements during
the same phase, with the same imaging sequence, and in the
same plane in serial examinations whenever possible.
 Performing these measurements with arterial phase and
diffusion-weighted MR imaging should be avoided if possible
Changes to Major Feature Definitions
Clarifications include distinctions
 Between nonrim APHE, a major feature of HCC, and
rim APHE, which is a criterion for inclusion in the LR-
M category.
 Between nonperipheral washout, a major feature of
HCC, and peripheral washout, which is a criterion for
inclusion in the LR-M category.
 Between enhancing capsule, a major feature of
HCC, and nonenhancing capsule, an ancillary
feature favoring HCC.
Changes to Major Feature Definitions
Changes to Major Feature Definitions
Ancillary Imaging Features
 Designated as optional.
 Can be used to upgrade or downgrade an
observation by no more than one category but cannot
be used to upgrade an observation to category LR-5.
 The ancillary features themselves are similar to those
described in the 2013 and 2014 versions of LI-RADS,
with two exceptions:
 First, the appearance of a lesion that was
identified at CT or MR imaging and seen as a
discrete nodule at nonenhanced US is now
considered an ancillary feature favoring
malignancy.
 Second, a nonenhancing capsule, defined as a
capsule that is not depicted as an enhancing rim
(ie, it does not meet the definition criteria for
capsule appearance), is considered an ancillary
feature that favors HCC in particular.
 More specifically, this is the description of a smooth
uniform sharp border around most or all of a lesion.
This border is distinct from the fibrotic tissue
around background nodules and does not enhance
during any phase of imaging. Nonenhancing
“capsules” typically are hypoattenutating at CT,
hypointense on nonenhanced or gadolinium-
enhanced T1- weighted MR images, and of
variable signal intensity on T2- and diffusion-
weighted MR images.
Assigning a LI-RADS Diagnostic
Category in Four Steps
Treatment Response Assessment
Categories and Criteria
 The inclusion of categories and criteria used to
assess residual or recurrent malignancy after local-
regional therapies is new in LI-RADS v2017.
 Performing post treatment imaging in 3-month
intervals and with use of the same imaging modality
(preferable) or another modality (acceptable) is
recommended in most cases.
 When assessing treatment response, the
radiologist must first decide whether the treated
lesion can be adequately evaluated and then
assign a category on the basis of the presence or
absence of features that are suggestive of viable
tumor
LR-TR Nonevaluable
A treatment response is categorized as LR-TR nonevaluable
when the treated lesion cannot be reliably evaluated owing to
image degradation or the omission of necessary
enhancement phases. This category is separate from LR-NC
(noncategorizable), which applies to nontreated lesions
 Thank you

More Related Content

What's hot

Interventions in liver tumors
Interventions in liver tumorsInterventions in liver tumors
Interventions in liver tumors
apurv11
 
Liver transplantation for HCC - pushing the limits
Liver transplantation for HCC - pushing the limitsLiver transplantation for HCC - pushing the limits
Liver transplantation for HCC - pushing the limits
Gian Luca Grazi
 
RCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell CarcinomaRCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell Carcinoma
Be Akash Sah
 
HCC premanagment
HCC  premanagmentHCC  premanagment
HCC premanagment
Susheel Kumar Yeshala
 
Diagnosis and treatment of pancreatic cancer
Diagnosis and treatment of pancreatic cancerDiagnosis and treatment of pancreatic cancer
Diagnosis and treatment of pancreatic cancer
Gian Luca Grazi
 
Session 2.3: Gabeau
Session 2.3: GabeauSession 2.3: Gabeau
Session 2.3: Gabeau
Albert Einstein Cancer Center
 
Liver diseases symposium interventional techniques and downstaging of hcc f...
Liver diseases symposium   interventional techniques and downstaging of hcc f...Liver diseases symposium   interventional techniques and downstaging of hcc f...
Liver diseases symposium interventional techniques and downstaging of hcc f...
pryce27
 
management of metastatic colorectal cancer
 management of metastatic colorectal cancer  management of metastatic colorectal cancer
management of metastatic colorectal cancer
Sujay Susikar
 
Surgical treatment of hepatocellular carcinoma
Surgical treatment of hepatocellular carcinomaSurgical treatment of hepatocellular carcinoma
Surgical treatment of hepatocellular carcinoma
Gian Luca Grazi
 
Hcc egyptian guidelines overview Prof ezz elarab
Hcc egyptian guidelines overview Prof ezz elarabHcc egyptian guidelines overview Prof ezz elarab
Hcc egyptian guidelines overview Prof ezz elarab
Mohammed Ezzelarab
 
surgical manag of colorectal liver mets
surgical manag of colorectal liver metssurgical manag of colorectal liver mets
surgical manag of colorectal liver mets
Dr Dharma ram Poonia
 
Minimally Invasive Liver Resection and Ablation For Malignancy
Minimally Invasive Liver Resection and Ablation For MalignancyMinimally Invasive Liver Resection and Ablation For Malignancy
Minimally Invasive Liver Resection and Ablation For Malignancy
Peninsula Coastal Region of Sutter Health
 
State of the art of robotic surgery in the liver
State of the art of robotic surgery in the liverState of the art of robotic surgery in the liver
State of the art of robotic surgery in the liver
Gian Luca Grazi
 
Management Of Liver M E T A S T A S I S Patient Selection
Management Of Liver   M E T A S T A S I S   Patient SelectionManagement Of Liver   M E T A S T A S I S   Patient Selection
Management Of Liver M E T A S T A S I S Patient Selection
Sumit Roy
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinoma
Jibran Mohsin
 
The Interplay Role of Liver Resection for Liver Transplantation
The Interplay Role of Liver Resection for Liver TransplantationThe Interplay Role of Liver Resection for Liver Transplantation
The Interplay Role of Liver Resection for Liver Transplantation
Gian Luca Grazi
 
Colorectal liver metastases (Dr Juan Carlos Meneu Diaz). Oncocir. Clinica Ruber
Colorectal liver metastases (Dr Juan Carlos Meneu Diaz). Oncocir. Clinica Ruber Colorectal liver metastases (Dr Juan Carlos Meneu Diaz). Oncocir. Clinica Ruber
Colorectal liver metastases (Dr Juan Carlos Meneu Diaz). Oncocir. Clinica Ruber
Oncocir (Unidad de Oncología Quirúrgica)
 
Management of colorectal liver metastasis
Management of colorectal liver metastasis Management of colorectal liver metastasis
Management of colorectal liver metastasis
Aditya Punamiya
 
Dr.yasar ahmed hcc with background
Dr.yasar ahmed hcc with backgroundDr.yasar ahmed hcc with background
Dr.yasar ahmed hcc with background
Yasar Hammor. MRCP(UK),FRCP
 
Git j club cupl or cup.
Git j club cupl or cup.Git j club cupl or cup.
Git j club cupl or cup.
Shaikhani.
 

What's hot (20)

Interventions in liver tumors
Interventions in liver tumorsInterventions in liver tumors
Interventions in liver tumors
 
Liver transplantation for HCC - pushing the limits
Liver transplantation for HCC - pushing the limitsLiver transplantation for HCC - pushing the limits
Liver transplantation for HCC - pushing the limits
 
RCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell CarcinomaRCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell Carcinoma
 
HCC premanagment
HCC  premanagmentHCC  premanagment
HCC premanagment
 
Diagnosis and treatment of pancreatic cancer
Diagnosis and treatment of pancreatic cancerDiagnosis and treatment of pancreatic cancer
Diagnosis and treatment of pancreatic cancer
 
Session 2.3: Gabeau
Session 2.3: GabeauSession 2.3: Gabeau
Session 2.3: Gabeau
 
Liver diseases symposium interventional techniques and downstaging of hcc f...
Liver diseases symposium   interventional techniques and downstaging of hcc f...Liver diseases symposium   interventional techniques and downstaging of hcc f...
Liver diseases symposium interventional techniques and downstaging of hcc f...
 
management of metastatic colorectal cancer
 management of metastatic colorectal cancer  management of metastatic colorectal cancer
management of metastatic colorectal cancer
 
Surgical treatment of hepatocellular carcinoma
Surgical treatment of hepatocellular carcinomaSurgical treatment of hepatocellular carcinoma
Surgical treatment of hepatocellular carcinoma
 
Hcc egyptian guidelines overview Prof ezz elarab
Hcc egyptian guidelines overview Prof ezz elarabHcc egyptian guidelines overview Prof ezz elarab
Hcc egyptian guidelines overview Prof ezz elarab
 
surgical manag of colorectal liver mets
surgical manag of colorectal liver metssurgical manag of colorectal liver mets
surgical manag of colorectal liver mets
 
Minimally Invasive Liver Resection and Ablation For Malignancy
Minimally Invasive Liver Resection and Ablation For MalignancyMinimally Invasive Liver Resection and Ablation For Malignancy
Minimally Invasive Liver Resection and Ablation For Malignancy
 
State of the art of robotic surgery in the liver
State of the art of robotic surgery in the liverState of the art of robotic surgery in the liver
State of the art of robotic surgery in the liver
 
Management Of Liver M E T A S T A S I S Patient Selection
Management Of Liver   M E T A S T A S I S   Patient SelectionManagement Of Liver   M E T A S T A S I S   Patient Selection
Management Of Liver M E T A S T A S I S Patient Selection
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinoma
 
The Interplay Role of Liver Resection for Liver Transplantation
The Interplay Role of Liver Resection for Liver TransplantationThe Interplay Role of Liver Resection for Liver Transplantation
The Interplay Role of Liver Resection for Liver Transplantation
 
Colorectal liver metastases (Dr Juan Carlos Meneu Diaz). Oncocir. Clinica Ruber
Colorectal liver metastases (Dr Juan Carlos Meneu Diaz). Oncocir. Clinica Ruber Colorectal liver metastases (Dr Juan Carlos Meneu Diaz). Oncocir. Clinica Ruber
Colorectal liver metastases (Dr Juan Carlos Meneu Diaz). Oncocir. Clinica Ruber
 
Management of colorectal liver metastasis
Management of colorectal liver metastasis Management of colorectal liver metastasis
Management of colorectal liver metastasis
 
Dr.yasar ahmed hcc with background
Dr.yasar ahmed hcc with backgroundDr.yasar ahmed hcc with background
Dr.yasar ahmed hcc with background
 
Git j club cupl or cup.
Git j club cupl or cup.Git j club cupl or cup.
Git j club cupl or cup.
 

Similar to 2017 version of li rads for ct and mr

bclc.pptx
bclc.pptxbclc.pptx
STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A...
STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A...STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A...
STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A...
accurayexchange
 
Session 2.3 Gabeau
Session 2.3 GabeauSession 2.3 Gabeau
Session 2.3 Gabeau
Albert Einstein Cancer Center
 
02.3 gabeau mac
02.3 gabeau mac02.3 gabeau mac
Neoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinoma
Neoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinomaNeoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinoma
Neoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinoma
Dr.Bhavin Vadodariya
 
Renal cell carcinoma
Renal cell carcinomaRenal cell carcinoma
Renal cell carcinoma
Dr. Sumit KUMAR
 
Monitoring after therapies for hcc
Monitoring after therapies for hccMonitoring after therapies for hcc
Monitoring after therapies for hcc
Dhaval Mangukiya
 
Highlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptxHighlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptx
Mona Quenawy
 
Ca Cervix Dr Naresh Jakhotia
Ca Cervix Dr Naresh JakhotiaCa Cervix Dr Naresh Jakhotia
Ca Cervix Dr Naresh Jakhotia
drnareshjakhotia
 
Surgeons view on AHA/ACC Coronary revascularisation guidelines .pptx
Surgeons view on  AHA/ACC Coronary revascularisation guidelines .pptxSurgeons view on  AHA/ACC Coronary revascularisation guidelines .pptx
Surgeons view on AHA/ACC Coronary revascularisation guidelines .pptx
Chaitanya Chittimuri
 
Management of ca lung - early stage -Dr Sumanth.pptx
Management of ca lung - early stage -Dr  Sumanth.pptxManagement of ca lung - early stage -Dr  Sumanth.pptx
Management of ca lung - early stage -Dr Sumanth.pptx
MSKumar16
 
Mangment of recurent sarcoma
Mangment of recurent sarcomaMangment of recurent sarcoma
Mangment of recurent sarcoma
King Hussien Cancer Center
 
Radiotherapy contouring guideline for non-hodgkin lymphoma
Radiotherapy contouring guideline for non-hodgkin lymphomaRadiotherapy contouring guideline for non-hodgkin lymphoma
Radiotherapy contouring guideline for non-hodgkin lymphoma
ketan kalariya
 
Staging in HCC.pptx
Staging in HCC.pptxStaging in HCC.pptx
Staging in HCC.pptx
Sankalp Singh
 
Intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma
Sujan Shrestha
 
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelinesRenal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
Dr. Naina Kumar Agarwal
 
Pancreatic cancer Management (pancreatic adenocarcinoma)
Pancreatic cancer Management (pancreatic adenocarcinoma)Pancreatic cancer Management (pancreatic adenocarcinoma)
Pancreatic cancer Management (pancreatic adenocarcinoma)
Dr mohamed Salat Gonjobe
 
PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Bi...
PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Bi...PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Bi...
PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Bi...
PVI, PeerView Institute for Medical Education
 
HCC MANGEMENT(RAD ONCO)
HCC MANGEMENT(RAD ONCO)HCC MANGEMENT(RAD ONCO)
HCC MANGEMENT(RAD ONCO)
Dr. Anukul Dutta
 
PERIAMPULLARY CARCINOMA.pptx
PERIAMPULLARY CARCINOMA.pptxPERIAMPULLARY CARCINOMA.pptx
PERIAMPULLARY CARCINOMA.pptx
masthan basha
 

Similar to 2017 version of li rads for ct and mr (20)

bclc.pptx
bclc.pptxbclc.pptx
bclc.pptx
 
STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A...
STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A...STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A...
STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A...
 
Session 2.3 Gabeau
Session 2.3 GabeauSession 2.3 Gabeau
Session 2.3 Gabeau
 
02.3 gabeau mac
02.3 gabeau mac02.3 gabeau mac
02.3 gabeau mac
 
Neoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinoma
Neoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinomaNeoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinoma
Neoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinoma
 
Renal cell carcinoma
Renal cell carcinomaRenal cell carcinoma
Renal cell carcinoma
 
Monitoring after therapies for hcc
Monitoring after therapies for hccMonitoring after therapies for hcc
Monitoring after therapies for hcc
 
Highlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptxHighlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptx
 
Ca Cervix Dr Naresh Jakhotia
Ca Cervix Dr Naresh JakhotiaCa Cervix Dr Naresh Jakhotia
Ca Cervix Dr Naresh Jakhotia
 
Surgeons view on AHA/ACC Coronary revascularisation guidelines .pptx
Surgeons view on  AHA/ACC Coronary revascularisation guidelines .pptxSurgeons view on  AHA/ACC Coronary revascularisation guidelines .pptx
Surgeons view on AHA/ACC Coronary revascularisation guidelines .pptx
 
Management of ca lung - early stage -Dr Sumanth.pptx
Management of ca lung - early stage -Dr  Sumanth.pptxManagement of ca lung - early stage -Dr  Sumanth.pptx
Management of ca lung - early stage -Dr Sumanth.pptx
 
Mangment of recurent sarcoma
Mangment of recurent sarcomaMangment of recurent sarcoma
Mangment of recurent sarcoma
 
Radiotherapy contouring guideline for non-hodgkin lymphoma
Radiotherapy contouring guideline for non-hodgkin lymphomaRadiotherapy contouring guideline for non-hodgkin lymphoma
Radiotherapy contouring guideline for non-hodgkin lymphoma
 
Staging in HCC.pptx
Staging in HCC.pptxStaging in HCC.pptx
Staging in HCC.pptx
 
Intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma
 
Renal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelinesRenal cell carcinoma: MAnagement guidelines
Renal cell carcinoma: MAnagement guidelines
 
Pancreatic cancer Management (pancreatic adenocarcinoma)
Pancreatic cancer Management (pancreatic adenocarcinoma)Pancreatic cancer Management (pancreatic adenocarcinoma)
Pancreatic cancer Management (pancreatic adenocarcinoma)
 
PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Bi...
PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Bi...PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Bi...
PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Bi...
 
HCC MANGEMENT(RAD ONCO)
HCC MANGEMENT(RAD ONCO)HCC MANGEMENT(RAD ONCO)
HCC MANGEMENT(RAD ONCO)
 
PERIAMPULLARY CARCINOMA.pptx
PERIAMPULLARY CARCINOMA.pptxPERIAMPULLARY CARCINOMA.pptx
PERIAMPULLARY CARCINOMA.pptx
 

More from vinothmezoss

Adnexal masses
Adnexal massesAdnexal masses
Adnexal masses
vinothmezoss
 
imaging of Testicular malignancies
imaging of Testicular malignanciesimaging of Testicular malignancies
imaging of Testicular malignancies
vinothmezoss
 
imaging of Orbital tumours
imaging of Orbital tumoursimaging of Orbital tumours
imaging of Orbital tumours
vinothmezoss
 
Imaging in Multiple sclerosis
Imaging in Multiple sclerosis   Imaging in Multiple sclerosis
Imaging in Multiple sclerosis
vinothmezoss
 
utrasound in Early pregnancy
utrasound in Early pregnancyutrasound in Early pregnancy
utrasound in Early pregnancy
vinothmezoss
 
Cns lymphomas
Cns lymphomasCns lymphomas
Cns lymphomas
vinothmezoss
 
imaging of soft tissue tumours
imaging of soft tissue tumoursimaging of soft tissue tumours
imaging of soft tissue tumours
vinothmezoss
 
Imaging of Non tubercular infections of the urinary tract
Imaging of Non tubercular infections of the urinary tractImaging of Non tubercular infections of the urinary tract
Imaging of Non tubercular infections of the urinary tract
vinothmezoss
 
Role of imaging in renal tuberculosis
Role of imaging in renal tuberculosisRole of imaging in renal tuberculosis
Role of imaging in renal tuberculosis
vinothmezoss
 
Imaging in inherited metabolic disorders
Imaging in inherited metabolic disordersImaging in inherited metabolic disorders
Imaging in inherited metabolic disorders
vinothmezoss
 

More from vinothmezoss (10)

Adnexal masses
Adnexal massesAdnexal masses
Adnexal masses
 
imaging of Testicular malignancies
imaging of Testicular malignanciesimaging of Testicular malignancies
imaging of Testicular malignancies
 
imaging of Orbital tumours
imaging of Orbital tumoursimaging of Orbital tumours
imaging of Orbital tumours
 
Imaging in Multiple sclerosis
Imaging in Multiple sclerosis   Imaging in Multiple sclerosis
Imaging in Multiple sclerosis
 
utrasound in Early pregnancy
utrasound in Early pregnancyutrasound in Early pregnancy
utrasound in Early pregnancy
 
Cns lymphomas
Cns lymphomasCns lymphomas
Cns lymphomas
 
imaging of soft tissue tumours
imaging of soft tissue tumoursimaging of soft tissue tumours
imaging of soft tissue tumours
 
Imaging of Non tubercular infections of the urinary tract
Imaging of Non tubercular infections of the urinary tractImaging of Non tubercular infections of the urinary tract
Imaging of Non tubercular infections of the urinary tract
 
Role of imaging in renal tuberculosis
Role of imaging in renal tuberculosisRole of imaging in renal tuberculosis
Role of imaging in renal tuberculosis
 
Imaging in inherited metabolic disorders
Imaging in inherited metabolic disordersImaging in inherited metabolic disorders
Imaging in inherited metabolic disorders
 

Recently uploaded

Main Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docxMain Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docx
adhitya5119
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
Scholarhat
 
Types of Herbal Cosmetics its standardization.
Types of Herbal Cosmetics its standardization.Types of Herbal Cosmetics its standardization.
Types of Herbal Cosmetics its standardization.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
The basics of sentences session 6pptx.pptx
The basics of sentences session 6pptx.pptxThe basics of sentences session 6pptx.pptx
The basics of sentences session 6pptx.pptx
heathfieldcps1
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
thanhdowork
 
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
Academy of Science of South Africa
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
Top five deadliest dog breeds in America
Top five deadliest dog breeds in AmericaTop five deadliest dog breeds in America
Top five deadliest dog breeds in America
Bisnar Chase Personal Injury Attorneys
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
amberjdewit93
 
World environment day ppt For 5 June 2024
World environment day ppt For 5 June 2024World environment day ppt For 5 June 2024
World environment day ppt For 5 June 2024
ak6969907
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
DRUGS AND ITS classification slide share
DRUGS AND ITS classification slide shareDRUGS AND ITS classification slide share
DRUGS AND ITS classification slide share
taiba qazi
 
How to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRMHow to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRM
Celine George
 
writing about opinions about Australia the movie
writing about opinions about Australia the moviewriting about opinions about Australia the movie
writing about opinions about Australia the movie
Nicholas Montgomery
 
A Independência da América Espanhola LAPBOOK.pdf
A Independência da América Espanhola LAPBOOK.pdfA Independência da América Espanhola LAPBOOK.pdf
A Independência da América Espanhola LAPBOOK.pdf
Jean Carlos Nunes Paixão
 
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
PECB
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
tarandeep35
 

Recently uploaded (20)

Main Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docxMain Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docx
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
 
Types of Herbal Cosmetics its standardization.
Types of Herbal Cosmetics its standardization.Types of Herbal Cosmetics its standardization.
Types of Herbal Cosmetics its standardization.
 
The basics of sentences session 6pptx.pptx
The basics of sentences session 6pptx.pptxThe basics of sentences session 6pptx.pptx
The basics of sentences session 6pptx.pptx
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
 
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
Top five deadliest dog breeds in America
Top five deadliest dog breeds in AmericaTop five deadliest dog breeds in America
Top five deadliest dog breeds in America
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
 
World environment day ppt For 5 June 2024
World environment day ppt For 5 June 2024World environment day ppt For 5 June 2024
World environment day ppt For 5 June 2024
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
DRUGS AND ITS classification slide share
DRUGS AND ITS classification slide shareDRUGS AND ITS classification slide share
DRUGS AND ITS classification slide share
 
How to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRMHow to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRM
 
writing about opinions about Australia the movie
writing about opinions about Australia the moviewriting about opinions about Australia the movie
writing about opinions about Australia the movie
 
A Independência da América Espanhola LAPBOOK.pdf
A Independência da América Espanhola LAPBOOK.pdfA Independência da América Espanhola LAPBOOK.pdf
A Independência da América Espanhola LAPBOOK.pdf
 
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
 

2017 version of li rads for ct and mr

  • 1. 2017 Version of LI-RADS for CT and MR Imaging: An Update DR.M.VINOTHKUMAR Apollo speciality hospital
  • 2. Introduction  The Liver Imaging Reporting and Data System (LI- RADS) is a reporting system created for the standardized interpretation of liver imaging findings in patients who are at risk for hepatocellular carcinoma (HCC).
  • 3. Overview of LI-RADS v2017  In version 2017, new LI-RADS categories have been introduced to better characterize observations for both diagnosis and treatment response assessment.  New content is aimed primarily at addressing gaps in prior versions, such as the lack of treatment response criteria and specific criteria for inclusion in the LR-M category (malignancy that may not be HCC).
  • 4. LI-RADS v2017 Diagnostic Population Inclusion criteria  Adult (older than 18 years) patients with cirrhosis,  patients with chronic hepatitis B,  patients with current or prior HCC with or without cirrhosis, including adult liver transplantation candidates and liver transplant recipients.
  • 5. Exclusion criteria  Cirrhosis due to a vascular disorder (eg, hereditary hemorrhagic telangiectasia, Budd-Chiari syndrome, nodular regenerative hyperplasia, or cardiac cirrhosis),  cirrhosis due to congenital hepatic fibrosis,  pediatric patients. Cirrhosis caused by vascular disorders are excluded from the LI-RADS diagnostic population because of the large number of arterialized nonmalignant hepatocellular nodules that may resemble HCC at imaging, which lowers diagnostic specificity .
  • 6.
  • 7. LR-NC (Not Categorizable)  The newly added LR-NC category is intended to allow the radiologist to defer designating a final LI-RADS category when technical limitations (ie, image degradation or omission) prevent the differential diagnosis from being meaningfully narrowed.  An observation ranged from probably benign to potentially malignant because dynamic phase imaging had not been performed, LR-NC would be an appropriate category.  For LR-NC observations, repeat imaging performed with all sequences at 3 months or sooner is usually appropriate or depending on the cause of image degradation, imaging with an alternative modality may be preferable.
  • 8. LR-TIV (Definitely Malignant with TIV)  An unequivocal TIV was previously categorized as an LR-5V lesion, although other malignancies such as cholangiocarcinoma and combination tumors also can invade veins.  Because TIVs can occur in non-HCC malignancies, in LI-RADS v2017 the category LR-5 is replaced with LRTIV, which can apply to HCC or other malignancies
  • 9. LR-M (probable or definite malignancy, not specific for HCC)  Prior versions include a list of ancillary features that are suggestive of other malignancies, but they do not provide specific guidelines for application of the features.
  • 10.
  • 11.
  • 12.
  • 13. These features are most closely associated with intrahepatic cholangiocarcinomas but may also be present in combination tumors (eg, hepatocholangiocarcinomas) and metastases.
  • 14. LR-M (probable or definite malignancy, not specific for HCC)  The updated, more explicit criteria for inclusion in the LR-M category are intended to preserve the specificity of the LR-5 category for HCC without loss of sensitivity for the detection of malignancy and to improve inter-reader agreement.  Many LR-M lesions represent HCC but do not meet the imaging criteria for this diagnosis.  Multidisciplinary discussion is usually required for the appropriate management of LR-M lesions.
  • 15. Changes to Major Feature Definitions Threshold growth  Minimal 5-mm increase in lesion size and either a 50% or greater increase in size before or at 6 months or a 100% or greater increase in size after 6 months.  A lesion that was previously unseen for up to 24 months but is now 10 mm in diameter or larger also is considered to have threshold growth.  It is imperative to perform comparative measurements during the same phase, with the same imaging sequence, and in the same plane in serial examinations whenever possible.  Performing these measurements with arterial phase and diffusion-weighted MR imaging should be avoided if possible
  • 16.
  • 17.
  • 18. Changes to Major Feature Definitions Clarifications include distinctions  Between nonrim APHE, a major feature of HCC, and rim APHE, which is a criterion for inclusion in the LR- M category.  Between nonperipheral washout, a major feature of HCC, and peripheral washout, which is a criterion for inclusion in the LR-M category.  Between enhancing capsule, a major feature of HCC, and nonenhancing capsule, an ancillary feature favoring HCC.
  • 19. Changes to Major Feature Definitions
  • 20. Changes to Major Feature Definitions
  • 21. Ancillary Imaging Features  Designated as optional.  Can be used to upgrade or downgrade an observation by no more than one category but cannot be used to upgrade an observation to category LR-5.  The ancillary features themselves are similar to those described in the 2013 and 2014 versions of LI-RADS, with two exceptions:  First, the appearance of a lesion that was identified at CT or MR imaging and seen as a discrete nodule at nonenhanced US is now considered an ancillary feature favoring malignancy.
  • 22.  Second, a nonenhancing capsule, defined as a capsule that is not depicted as an enhancing rim (ie, it does not meet the definition criteria for capsule appearance), is considered an ancillary feature that favors HCC in particular.  More specifically, this is the description of a smooth uniform sharp border around most or all of a lesion. This border is distinct from the fibrotic tissue around background nodules and does not enhance during any phase of imaging. Nonenhancing “capsules” typically are hypoattenutating at CT, hypointense on nonenhanced or gadolinium- enhanced T1- weighted MR images, and of variable signal intensity on T2- and diffusion- weighted MR images.
  • 23.
  • 24.
  • 25. Assigning a LI-RADS Diagnostic Category in Four Steps
  • 26.
  • 27.
  • 28.
  • 29. Treatment Response Assessment Categories and Criteria  The inclusion of categories and criteria used to assess residual or recurrent malignancy after local- regional therapies is new in LI-RADS v2017.  Performing post treatment imaging in 3-month intervals and with use of the same imaging modality (preferable) or another modality (acceptable) is recommended in most cases.  When assessing treatment response, the radiologist must first decide whether the treated lesion can be adequately evaluated and then assign a category on the basis of the presence or absence of features that are suggestive of viable tumor
  • 30. LR-TR Nonevaluable A treatment response is categorized as LR-TR nonevaluable when the treated lesion cannot be reliably evaluated owing to image degradation or the omission of necessary enhancement phases. This category is separate from LR-NC (noncategorizable), which applies to nontreated lesions
  • 31.